FDA approves once-monthly schizophrenia drug from Durect, Indivior

Durect Corp. (NASDAQ:DRRX) and Indivior plc (LSE:INDV) said FDA approved Perseris risperidone (RBP-7000) to treat schizophrenia

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE